Abstract: An electronic package includes a substrate wafer with an interconnect network. A first chip is fixed to a front of the substrate, connected to the interconnect network and encapsulated by a body. A second chip is placed on a back side of the substrate wafer and connected to the interconnect network by back-side connection elements interposed between the back side of the substrate and a front side of the second chip. Front-side connection elements are placed on the front side of the substrate and connected to the interconnect network. The connection elements extend beyond the frontal face of the body. The package may be mounted on a board with an interposed thermally conductive material.

Abstract: The invention relates to the use of imidazole derivatives of the formula (1): in which A, R?1, R?2 and R?3 are as defined in the description, as AMPK activators. The invention also relates to processes for the preparation of the said compounds, to their uses for the preparation of medicaments for the treatment of insulin resistance, diabetes and related pathologies, and also obesity, and to the pharmaceutical compositions comprising them. Certain compounds of the formula (1) are novel and, in this respect, also form part of the invention.

Abstract: The present invention relates to the use of a 4-oxobutanoic acid derivative for the preparation of a pharmaceutical composition for treating inflammation.

Abstract: The invention relates to the use of imidazole derivatives of the formula (1): in which A, R?1, R?2 and R?3 are as defined in the description, as AMPK activators. The invention also relates to processes for the preparation of the said compounds, to their uses for the preparation of medicaments for the treatment of insulin resistance, diabetes and related pathologies, and also obesity, and to the pharmaceutical compositions comprising them. Certain compounds of the formula (1) are novel and, in this respect, also form part of the invention.

Abstract: The present invention relates to the use of at least one compound with inhibitory activity on kynurenine 3-hydroxylase for the preparation of a medicament for the prevention and/or treatment of diabetes.

Abstract: The present invention relates to the use of at least one compound with inhibitory activity on kynurenine 3-hydroxylase, for the preparation of a medica ment for increasing the number of islets of Langerhans cells, which is intended especially for the prevention and/or treatment of diabetes.

Abstract: The present invention relates to a pharmaceutical composition comprising, as active principles, a 4-oxobutanoic acid and an ?-glucosidase inhibitor, in combination with one or more pharmaceutically acceptable excipients. These compositions are particularly suitable for treating diabetes.

Abstract: The present invention relates to a pharmaceutical composition comprising, as active principles, metformin, optionally in the form of one of it its pharmaceutically acceptable salts, and a 4-oxobutanoic acid, in combination with one or more pharmaceutically acceptable excipients. These compositions are particularly suitable for treating non-insulin-dependent diabetes.

Abstract: The present invention relates to the use of a 4-oxobutanoic acid derivative for the preparation of a pharmaceutical composition for treating inflammation.

Abstract: Piperazine derivatives of formula (I) wherein Z, X, n, Ar and i have the meanings defined herein are usefull in the treatment of pathologies associated with insulin-resistance syndrome.

Abstract: The present invention relates to a continuous process for the manufacture of potassium chlorate by coupling with a plant for the production of sodium chlorate by electrolysis, the said plant comprising a source of NaCl solution, (1), a loop for purification of the said solution (2--2', 3), an electrolysis device (4), a storage tank (5), if appropriate, and a crystallizer (6) in which the crystallization and the separation of NaClO.sub.3 crystals are preferably carried out, wherein circulating liquid is removed downstream of the said electrolysis device (4), a concentrated solution of potassium chloride is added to said liquid, precipitation (11) of the potassium chlorate is caused by any known means, the said potassium chlorate is separated off and the mother liquor from crystallization of the said potassium chlorate is recycled into the said purification loop (2--2', 3) of the sodium chlorate production plant.